More Stories

Informist, Friday, Feb. 27, 2026

 

MUMBAI – Shares of pharmaceutical companies are expected to move in a range next week. Analysts are bullish on the sales prospects for large pharmaceutical companies owing to the upcoming launch of generic glucagon-like peptide-1 drugs in India on Mar. 21, which is driving some investors to buy these stocks. However, expectations of a soft March quarter for US exports due to a slump in generic Revlimid sales is a key reason why caution around these stocks still remains, analysts said.

 

There is uncertainty about where the US import tariff rates will end up, as it has raised concern for several sectors. However, pharmaceutical players are relatively shielded from this turmoil as several key members of the US Senate have voiced their support for continuing zero-tariffs on generic drugs, said Mehul Sheth, a research analyst at HDFC Securities. "While the tariffs applicable under Section 232 are still under review, early indications suggest that generic drugs will continue to be exempted from the tariffs levied on branded and patented drugs," he said.

 

The launch of Semaglutide will aid the sales of domestic players in the upcoming quarters, Sheth said. He expects around 15–20 players entering the weight-loss drug market in March, which will drive up the competition. However, since this market is so under-penetrated, companies will have a large growth opportunity, the analyst said. Dr. Reddy's Laboratories Ltd. is set to launch its generic on the day the patent for Semaglutide expires, on Mar. 21.

 

Several other pharmaceutical companies already have pre-requisite approvals for generic Semaglutide launch, while others are looking to enter the domestic GLP-1 market when the patent for the drug expires in India.

 

Analysts said that the decline in sales of generic Revlimid will likely hurt pharmaceutical players even more in the March quarter. More diverse offerings in the US markets will likely help companies recover slightly from this drop in sales, according to analysts. However, Sheth added that he hasn't yet seen a product that can help offset this weakness.

For the week ended Friday, the Nifty Pharma index ended 2% higher at 22952.35 points. Mankind Pharma Ltd., Laurus Labs Ltd., and Ipca Laboratories Ltd. rose 5–11%. Piramal Pharma Ltd., Wockhardt Ltd., and Gland Pharma Ltd. were the worst hit stocks, ending flat to 3% lower. 

 

"The Nifty Pharma index has been trading within a broad congestion range, facing multiple resistances between 23400 and 23800 points, with immediate support in the 22100–22300 range," said Vipin Kumaar, derivative and technical analyst at Globe Capital Market. "On Friday, the index retreated after meeting resistance at the upper band of this zone," he added. The analyst expects the Nifty Pharma index to continue its side-way movement within the 22100–23500 range over the coming week.

 

TOP HEADLINES

 

* US FDA tags Lupin's Goa unit as 'voluntary action indicated'
* Glenmark Pharma US arm to launch sodium phosphates injection, sale from Apr
* SC upholds summons against Panacea Biotec for discrepancy in labelling drug
* OneSource Specialty gets bourses no-objection letter for 4 cos' amalgamation
* Aurobindo Pharma arm gets US FDA final nod to make, mkt Everolimus tablets
* Alembic Pharma gets US FDA final approval for Lamotrigine tablets
* Maharashtra GST dept conducts search ops at Lupin's office in Mumbai
* Zydus Life plans India launch of Semaglutide injection as patent ends March
* Biocon gets US FDA nod to commercialise Liraglutide drug in US
* Lupin set to launch brivaracetam in US after getting regulator's approval
* Dr Reddy's says US SEC not to act against co over alleged payments in Ukraine
* Delhi HC bench says plea to revoke patent can be filed even after expiry
* Aurobindo Pharma sets up arm to expand contract manufacturing operations
* Alembic Pharma gets US FDA final OK for efinaconazole topical solution
* Caplin Point arm gets US FDA approval for sodium phosphate injection vials
* Eris Lifesciences, Natco Pharma partner to launch semaglutide in India
* NSE, BSE to discontinue F&O contracts of Tata Tech, Torrent Pharma, 2 others
* Torrent Group starts diagnostic laboratory in Navi Mumbai
* Jasti Family Trust sells 2% more in Cohance Life after selling 1.8% last wk
* Lupin gets European Commission's nod for ranibizumab-biosimilar Ranluspec
* SC notice to govt against ban on fixed dose combination for type-II diabetes
* Cipla says US FDA issues official action vs lanreotide supplier Pharmathen
* LIC buys 2% stake in Cipla over 3 months, stake increases to 9.1%

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	26530.00	0.90	26920.00	25880.00
Alkem Laboratories	5639.50	4.60	5845.80	5510.80
Aurobindo Pharma	1220.40	5.30	1250.60	1199.20
Biocon	389.80	1.50	398.30	384.50
Cipla	1348.20	0.50	1366.30	1329.50
Divi's Laboratories	6408.50	1.90	6513.80	6330.80
Dr Reddy's Laboratories	1286.30	0.50	1332.90	1254.90
Gland Pharma	1822.20	0.00	1874.90	1782.50
GlaxoSmithKline Pharmaceuticals	2571.60	(-)1.00	2657.30	2523.10
Glenmark Pharmaceuticals	2136.70	4.60	2181.00	2094.20
Granules India	582.25	(-)2.80	593.70	574.40
Ipca Laboratories	1528.90	5.50	1560.40	1488.20
Laurus Labs	1075.80	5.60	1113.20	1049.20
Lupin	2301.90	3.70	2354.60	2265.40
Natco Pharma	988.50	10.90	1021.50	943.50
Pfizer	5062.20	2.70	5187.40	4957.40
Sanofi India	3965.10	(-)1.50	4079.60	3898.80
Sun Pharmaceutical Industries	1737.00	0.70	1809.20	1694.80
Torrent Pharmaceuticals	4333.30	2.20	4462.60	4258.00
Zydus Lifesciences	921.70	2.30	949.40	902.70
Index	Levels
Nifty Pharma	22952.35	2.20	23441.90	22672.40
Nifty 50	25178.65	(-)1.50	25600.60	24930.40
S&P Bse Sensex	81287.19	(-)1.80	82651.20	80477.20

 

 

End

 

Reported by Eshitva Prakash

Edited by Akul Nishant Akhoury

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000/+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.